ArticleAmerican journal of hematology2013

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.

Thomas E Witzig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.